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Introduction
Primary orthostatic tremor (POT) is a disorder characterized by tremor 
and unsteadiness. It only occurs when the patient is upright and immobile 
and stops once the patient walks, sits down, or lies down.1 Patients report 
a subjective feeling of  instability that impacts their quality of  life and may 
affect their activities of  daily living, with many such patients experiencing 
anxiety, depression, and social phobia.2
This disease is very uncommon.3 Its prevalence, furthermore, is 
unknown, which means it is very difficult to perform therapeutic trials. 
Medication, although it may provide some mild relief, is largely 
ineffective.1
Recently, it has been reported complete resolution of  POT symptoms 
in two patients using low doses of  perampanel, an antiepileptic drug that 
blocks glutamate-mediated postsynaptic excitation.4,5 In the current study, 
we describe our experience of  using perampanel in 20 patients with POT. 
Although ours was not a controlled trial, our findings and conclusions 
may be of  interest due to the low prevalence of  this disorder.
Patients and methods
Between January 2018 and January 2019, patients with POT were 
recruited through contact initiated by a French group of  patients with 
POT. Recruited were 20 patients whose neurologist had acceded to their 
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Abstract
Background:  Primary orthostatic tremor (POT) is a rare disorder for which current treatments are largely ineffective. Following up on our recent report of  com-
plete resolution of  POT symptoms in a patient using low doses of  perampanel, we describe our experience of  perampanel in 20 patients.
Methods:  Twenty patients whose neurologists prescribed perampanel were recruited. Initial dose was 2 mg/day, which was increased to 4 mg/day after the first 
month. Treatment efficacy was self-scored from +3 to −3 at 1 and 3 months.
Results:  Eight patients withdrew due to adverse effects. Of  the 12 patients who completed the study, 92% indicated that their POT symptoms had improved after 
1 month, with 75% indicating moderate to marked improvement (mean score 1.9 ± 0.9). This improvement was not sustained by follow-up at 3 months (mean score 
0.9 ± 1.3). A rebound of  POT symptoms that lasted 2–6 weeks was observed in most patients who withdrew.
Discussion:  Our experience with this series of  cases points to the potential of  low-dose perampanel as a treatment for POT, although poor tolerance and the 
possibility of  a non-persistent therapeutic benefit need to be considered. Controlled studies are needed to confirm these findings.
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request for a perampanel prescription. Electromyography (EMG) data 
were not available for any patient.
Patients were informed that they could withdraw at any time and 
were also guaranteed the anonymity and confidentiality of  their data. 
Informed consent was considered implicit in the patient agreeing to pro-
vide essential demographic and clinical data, monitor and record treat-
ment efficacy and adverse events, and provide this information to the 
patient coordinator for email transmission to the trial doctors.
Treatment duration was 3 months, and posology was 2 mg/day 
for the first month, which was increased to 4 mg/day for the remain-
ing 2 months. Perampanel was taken concurrently with any anti-
tremor medication that the patients were taking on while commencing 
the study.
Treatment efficacy was measured in terms of  symptom improve-
ment using a simple self-administered subjective scale, based on part 
C of  Fahn-Tolosa-Marin Tremor Clinical Rating Scale,6 scored as fol-
lows: 0 = no change; +1 = slight improvement; +2 = moderate 
improvement; +3 = marked improvement; −1 = slight worsening; 
−2 = moderate worsening; and −3 = marked worsening. Adverse 
effects were also recorded.
Patients notified their scores and any adverse event 1 and 3 months 
after starting treatment with perampanel. Patients who suffered any 
adverse effect that lasted more than last clinical control (3 months) were 
followed until symptoms reverted.
Results
The patients recruited for the study (n = 20) had a mean age of  
68.9 ± 6.3 years, 16 were women, and 17 were being treated with anti-
tremor medication. Mean evolution of  the disease was 14.4 ± 6.9 years. 
Of  the 20 patients included, 12 completed the study. After 1 month, 
11 patients showed some improvement in POT symptoms: three, six, 
and two patients scored their improvement as marked, moderate, and 
mild, respectively, and a single patient reported no change.
After 3 months, however, the degree of  improvement decreased, with 
only a single patient indicating marked improvement, four and five 
patients indicating moderate and mild improvement, respectively, and 
two patients reporting no change.
The mean improvement score was 1.9 ± 0.9 after 1 month, falling to 
0.9 ± 1.3 after 3 months. Non-persistence of  the therapeutic effect was 
observed in 50% of  patients.
Of  the 20 included patients, eight withdrew in a mean of  10 ± 5 days 
due to adverse effects: dizziness and instability with increased falls 
(n = 8), weight gain (n = 2), and depression (n = 2). No further patients 
withdrew, although following the dose increase to 4 mg/day after the 
first month, 8 of  the remaining 12 patients reverted to 2 mg/day due to 
mild dizziness and instability.
A rebound in POT symptoms (worse unsteadiness symptoms than 
patients ever had before) lasting 2–6 weeks was observed in six of  the eight 
patients who withdrew. Of  the 12 patients who completed the study, eight 
opted to continue with perampanel treatment after the study.
The demographic and clinical characteristics of  the patients are 
summarized in Table 1.
Discussion
For our case report series of  patients with POT, we observed that 
perampanel improved POT symptoms over 1 month of  treatment in 
nearly all (92%) of  the 12 patients who completed the study, with 75% 
showing moderate to marked improvement. However, this improvement 
was not sustained over the 3 months of  the study.
Currently, the only treatment administered for POT is symptomatic,1 
mainly clonazepam or gabapentin as first-line agents, or primidone, val-
proic acid, propranolol, or bromazepam.1,7,8 In most cases, however, 
medication benefits dissipate over time.1 Non-responders may benefit 
from bilateral thalamic deep brain stimulation of  the ventral intermedi-
ate nucleus.9
We recently reported complete resolution of  POT symptoms in a 
patient using low doses of  perampanel.4 After 18 months of  treatment, 
the benefits of  perampanel persist for this patient at a dose of  2 mg/day. 
Neurophysiology revealed the persistence of  subclinical EMG findings 
for POT in this patient, which would confirm a symptomatic rather 
than an etiological effect of  this drug.
Perampanel and its indications, pathophysiology and mechanisms of  
action have been fully documented elsewhere.4,10–15
Our study pointed to three main drawbacks of  perampanel as a 
treatment for POT. First, tolerance was poor, with 40% of  recruited 
patients withdrawing due to adverse effects (dizziness and instability, 
weight gain, and depression); furthermore, only 4 of  the 12 patients who 
completed the study were able to tolerate doubling the dose to 4 mg/
day after the first month.
In patients with epilepsy, perampanel appears to be associated with a 
relatively low incidence of  serious adverse effects, most especially at low 
doses.16,17 Predictable side effects, such as somnolence and dizziness, 
tend to be observed more frequently at higher doses. While the fact that 
psychiatric adverse effects, mainly irritability and aggression, occur at a 
greater rate with the use of  perampanel than with a placebo is a poten-
tial concern, the incidence of  serious psychiatric effects is nevertheless 
low. In our study, poor tolerance, as manifested in dizziness and instabil-
ity, weight gain, and depression, may have been due to perampanel 
interaction with the concomitant anti-tremor medication (clonazepam, 
gabapentin, pregabalin, lorazepam, and/or oxycodone) taken by 17 of  
the included 20 patients.
A second issue with perampanel as a treatment for POT was that the 
therapeutic benefit failed to persist in around 50% of  our patients after 
3 months of  treatment. This effect has not been described for peram-
panel used to treat patients with epilepsy, but has been reported for 
POT pharmacological trials with other anti-epileptic drugs1; this possi-
bly points to a greater tolerance of  anticonvulsant drugs by patients with 
POT. The reason for the non-persistence of  therapeutic benefit is not 
clear. One possibility is the existence of  a placebo effect lasting for some 
weeks. Another possibility is that the reduced efficacy may result from a 
dose increase from 2 to 4 mg/day. Efficacy may be greater at low doses, 
as higher doses would increase the adverse effects and hide anti-tremor 
efficacy. Further studies are needed to clarify this issue.
A final drawback with perampanel was the lengthy rebound of  POT 
symptoms in most of  the patients who discontinued perampanel. 
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Table 1. Patient Characteristics









1 month 3 months
1 65, F 17 GBP 2 +2 +1 No Weight gain, instability
2+ 66, F 5 None 2 +3 +3 N/A Mild dizziness
3* 78, F 31 CLN N/A N/A N/A Yes Dizziness, asthenia
4* 78, M 15 None N/A N/A N/A Yes Instability, dizziness
5* 65, F 24 CLN N/A N/A N/A Yes Tremor, dizziness
6* 72, F 5 CLN, PRG N/A N/A N/A Yes Tremor, instability
7* 75, M 17 CLN N/A N/A N/A N/A Instability
8+ 70, F 20 CLN, PRG 2 +2 +2 N/A None
9+ 71, F 14 CLN 4 +2 +2 N/A None
10* 75, M 8 TAR, LOR N/A N/A N/A Yes Depression
11* 53, F 11 None N/A N/A N/A N/A Depression
12+ 75, F 20 CLN 4 +2 +1 N/A None
13 66, F 15 CLN 2 +1 0 No Instability
14* 62, F 20 PRG N/A N/A N/A Yes Instability
15+ 68, F 7 GBP, CLN 4 +3 +2 N/A Weight gain
16+ 65, F 5 CLN 2 +3 +1 N/A None
17 60, F 10 CLN 2 0 0 No None
18+ 70, M 15 CLN 2 +2 +2 N/A None
19+ 75, F 10 GBP 4 +1 +1 N/A None
20 70, F 20 PRG 2 +2 +1 No Mild dizziness
Abbreviations: CLN, clonazepam; F, female; GBP, gabapentin; LOR, lorazepam; M, male; N/A, not applicable OXC, oxycodone; PRG, pregabalin.
*Indicates withdrawal.
+Indicates continuation beyond the study period.
The rebound effect persisted for several weeks after discontinuation, 
probably due to the long half-life of  perampanel.
The main limitation of  our study is its non-controlled design and the 
absence of  an objective measure of  improvement in POT symptoms. 
Nonetheless, the rarity and low prevalence of  this disease would suggest 
that our findings are of  interest.
Our experience with this series of  cases points to the potential of  low-
dose perampanel as a treatment for POT, although poor tolerance and 
the possibility of  a non-persistent therapeutic benefit need to be consid-
ered. Controlled studies are needed to confirm these findings.
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